Ignite Creation Date:
2024-05-05 @ 11:46 PM
Last Modification Date:
2024-10-26 @ 10:39 AM
Study NCT ID:
NCT01416376
Status:
COMPLETED
Last Update Posted:
2017-06-15
First Post:
2011-07-28
Brief Title:
Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation
Sponsor:
Sirtris a GSK Company
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Double Blind Placebo Controlled Phase I Dose-ranging Study to Evaluate the Activity of SRT2379 on Endotoxin Induced Inflammatory Response in Healthy Male Subjects
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
SRT2379 is a potent small molecule activator of SIRT1 that has been found to inhibit systemic inflammation induced by intravenous injection of lipopolysaccharide LPS in mice The objective of this study is to determine the effect of a single administration of SRT2379 at multiple-dose levels on the inflammatory response to low dose endotoxin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None